🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jesse Yu

Rapt Therapeutics (United States)

ORCID: 0000-0001-5784-3074

Materials ScienceImmunology and MicrobiologyComputer ScienceMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis”.

Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis

PLoS ONE(2020)10.1371/journal.pone.0228557

N/A

0DataRank · unranked

13 citations

Jesse Yu, James I. Griffin, Yan Wu, Linxi Zhu, Lisa A. McConnachie +2 more

ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models

Pharmaceutics(2021)10.3390/pharmaceutics14010089

N/A

0DataRank · unranked

18 citations

Qingxin Mu, Jesse Yu, James I. Griffin, Xiaolin Xu, Rodney J. Y. Ho +1 more

Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response

Pharmacology & Therapeutics(2022)10.1016/j.pharmthera.2022.108108

N/A

0DataRank · unranked

97 citations

Qingxin Mu, Millie Fung, Xiaolin Xu, Linxi Zhu, Rodney J. Y. Ho +1 more

Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression

Cancers(2024)10.3390/cancers16162792

N/A

0DataRank · unranked

1 citations

Xiaolin Xu, James I. Griffin, Qingxin Mu, Rodney J. Y. Ho, Jesse Yu